Key result
Metabolic syndrome was significantly associated with a higher prevalence of silent brain infarctions (75% vs 23.8%, p=0.001) and preclinical carotid atherosclerosis compared to controls.
Why the study?
Does metabolic syndrome increase the risk of subclinical cerebral atherosclerosis and silent brain infarction in asymptomatic individuals?
Case-Control (n=80)
No
Does metabolic syndrome increase the risk of subclinical cerebral atherosclerosis and silent brain infarction in asymptomatic individuals?
Absolute Event Rate: 75% vs 23.8%
p-value: p=0.001
Metabolic syndrome is significantly associated with mild to moderate carotid atherosclerosis and silent brain infarcts in asymptomatic individuals, highlighting the need for early risk factor modification.
May support cerebrovascular surveillance in metabolic syndrome; hypothesis-generating, requiring prospective confirmation before practice change.
Background: The metabolic syndrome (MetS) is a clustering of vascular risk factors that tend to increase the risk of occurrence of diabetes mellitus type 2 (DMT2), cardiovascular and cerebro-vascular ischemic events. The aim of the present study is to investigate the association of extra-cranial and intracranial arterial atherosclerosis as well as silent brain infarction (SBI) with MetS, thereby determining the potential cerebrovascular atherosclerotic risk of MetS in the Egyptian population. Methods: A case control study was conducted on 50 Egyptian subjects with MetS and 30 without with age range from 40 - 60 years old. All participants were free from cerebrovascular ischemic events [stroke or transient ischemic attack (TIA)]. All participants underwent complete neurological examination, assessment of the diagnostic criteria for MetS, carotid and transcranial duplex ultrasonography (U/S) and brain MRI. Results: Preclinical carotid atherosclerosis (athero-sclerotic plaques with <50% stenosis) was associated with MetS (P value = 0.02) that persisted after adjustment for age and other confounders. There was no significant association between increased intima media thickness (IMT) and MetS. There was non-significant association between MetS and intracranial atherosclerotic disease (ICAD) or the degree of intracranial stenosis (ICS). Conversely, there was a highly significant association between MetS and SBI even after adjustment for age and other confounders (P value = 0.001). Conclusion: Metabolic syndrome is an important factor associated with mild to moderate atherosclerosis (<50% stenosis) and silent brain infarcts among asymptomatic individuals. Interventions to reduce MetS are important for prevention of subclinical and clinical cerebral atherosclerotic disease.
No takes yet. Share an insight, caveat, or question.
Elwan et al. (2016) conducted a case-control in Metabolic Syndrome (n=80). Metabolic Syndrome vs. Subjects with 1 or 2 vascular risk factors (not fulfilling MetS criteria) was evaluated on Silent brain infarction (SBI) on MRI (p=0.001). Metabolic syndrome was significantly associated with a higher prevalence of silent brain infarctions (75% vs 23.8%, p=0.001) and preclinical carotid atherosclerosis compared to controls.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: